No Data
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
The Pacific Securities: The Sector's profits improved significantly in Q1, and the pharmaceutical industry is expected to see a rapid increase in concentration.
The trend of increasing concentration in the pharmaceutical industry and the strong becoming stronger is expected to continue to strengthen.
Sinopharm Group Reports Stable Earnings Amid Revenue Dip
Sinopharm's Q1 Profit Jumps
SINOPHARM released its quarterly performance, with a net income of 1.457 billion yuan, an increase of 2.59% year-on-year.
SINOPHARM (01099) released the financial information for the quarter ending March 31, 2025, with total operating revenue of 141.662 billion yuan, a year-on-year decrease of 3.81%; net income attributable to shareholders of the parent company was 1.457 billion yuan, a year-on-year increase of 2.59%; basic EPS was 0.47 yuan.
SINOPHARM (01099.HK): In the first quarter, the net income attributable to the parent company was 1.457 billion yuan, an increase of 2.6% year-on-year.
On April 28, Gelonghui reported that SINOPHARM (01099.HK) announced that for the three months ending March 31, 2025, it achieved total operating revenue of 141.662 billion yuan, a year-on-year decrease of 3.81%; net income attributable to the parent company's owners was 1.457 billion yuan, a year-on-year increase of 2.6%; EPS was 0.47 yuan.
Cui Nyonya Kueh :
Musang Siguntang : ???